Journal article · 2026 · Open access

Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy

Rui Chen, Letao Xu, Alexander H. Staudacher, Xing Wang, Ruoxuan Jia, John W. Finnie, Xiaoyan Wang, Dawn M. Whelan, Michael Paul Brown, Chun‐Xia Zhao

Science Advances, 12(37), eaed9568 · Published 11 September 2026 · DOI 10.1126/sciadv.aed9568

Open full textCite this paper

In brief

“Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy” is a 2026 journal article by Rui Chen and 9 co-authors, published in Science Advances. OpenAlex counts 1 citations as of 18 November 2026, which puts it in the top 9% of works published in 2026 by citations. It is open access under a CC BY-NC licence: the full text is free to read at Science Advances.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
1.90
References
62
Authors
10

Abstract

The immunosuppressive tumor microenvironment (TME) remains one of the main obstacles that limit responsiveness to immunotherapy. Recently, lipid nanoparticles carrying messenger RNA (mRNA) have emerged as a promising strategy to modulate the immunosuppressive TME, with the ultimate goal of sustaining anticancer immunity of cytotoxic T lymphocytes (CTLs). However, there are challenges with mRNA-based cytokine/chemokine therapies such as the lack of specific targeting, low therapeutic efficacy, and elevated toxicity, raising concerns about their clinical translation. Here, we have developed an antibody-coated lipid nanoparticle (Ab-LNP) delivery system that targets the protein triggering receptor expressed on myeloid cells 2 (TREM2) expressed by tumor-associated macrophages (TAMs). We demonstrate that codelivery of a Toll-like receptor agonist and CXCL9-encoding mRNA encapsulated in our Ab-LNP successfully ameliorates immunosuppression and improves tumor infiltration and activity of CTLs. Further combination with immune checkpoint inhibitors against PD-L1 and CTLA-4 promoted a CTL-favoring immunological environment and durable memory immunity. Our Ab-LNPs targeting TAMs highlight the potential of reprogramming immunosuppressive TME to enhance CTL activity for improved response to cancer immunotherapy.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Chen, R., Xu, L., Staudacher, A. H., Wang, X., Jia, R., Finnie, J. W., Wang, X., Whelan, D. M., Brown, M. P., & Zhao, C. (2026). Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy. Science Advances, 12(37), eaed9568. https://doi.org/10.1126/sciadv.aed9568

MLA 9

Chen, Rui, et al. “Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy.” Science Advances, vol. 12, no. 37, 2026, p. eaed9568. https://doi.org/10.1126/sciadv.aed9568.

Chicago

Chen, Rui, Letao Xu, Alexander H. Staudacher, Xing Wang, Ruoxuan Jia, John W. Finnie, Xiaoyan Wang, Dawn M. Whelan, Michael Paul Brown, and Chun‐Xia Zhao. 2026. “Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy.” Science Advances 12 (37): eaed9568. https://doi.org/10.1126/sciadv.aed9568.

Harvard

Chen, R. et al. (2026) ‘Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy’, Science Advances, 12(37), p. eaed9568. doi:10.1126/sciadv.aed9568.

IEEE

R. Chen et al., “Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy,” Science Advances, vol. 12, no. 37, p. eaed9568, 2026, doi: 10.1126/sciadv.aed9568.

BibTeX

@article{chen2026targeting,
  title     = {{Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy}},
  author    = {Chen, Rui and Xu, Letao and Staudacher, Alexander H. and Wang, Xing and Jia, Ruoxuan and Finnie, John W. and Wang, Xiaoyan and Whelan, Dawn M. and Brown, Michael Paul and Zhao, Chun‐Xia},
  journal   = {Science Advances},
  year      = {2026},
  volume    = {12},
  number    = {37},
  pages     = {eaed9568},
  doi       = {10.1126/sciadv.aed9568},
  url       = {https://doi.org/10.1126/sciadv.aed9568}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses

  • tumor-associated macrophages
  • TREM2
  • mRNA vaccine delivery
  • cytotoxic T lymphocytes
  • immunosuppressive tumor microenvironment
  • TLR agonists
  • CXCL9
  • PD-L1 blockade

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Chen, R., Xu, L., Staudacher, A. H., Wang, X., Jia, R., Finnie, J. W., Wang, X., Whelan, D. M., Brown, M. P., & Zhao, C. (2026). Targeting tumor-associated macrophages using mRNA lipid nanoparticles for cytotoxic T lymphocyte–mediated cancer immunotherapy. Science Advances, 12(37), eaed9568. https://doi.org/10.1126/sciadv.aed9568

How many times has this paper been cited?

1 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Science Advances: sign in and open the full text from this page.

Who wrote this paper?

Rui Chen, Letao Xu, Alexander H. Staudacher, Xing Wang, Ruoxuan Jia, John W. Finnie, Xiaoyan Wang, Dawn M. Whelan, Michael Paul Brown, Chun‐Xia Zhao.

What is the DOI of this paper?

10.1126/sciadv.aed9568, permanently at https://doi.org/10.1126/sciadv.aed9568. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.